Introduction Several licensed and investigational vaccines have lower efficacy, and induce
impaired immune responses, in low-income versus high-income countries and in rural …

Background Schistosoma infection is associated with immune modulation that can influence
responses to non-schistosome antigens. Vaccine responses may be impaired in S. mansoni …

Background Praziquantel-based mass treatment is the main approach to controlling
schistosomiasis mansoni in endemic areas. Interventions such as provision and use of safe …

Schistosomiasis is a debilitating helminthiasis which commonly establishes as a chronic
infection in people from endemic areas. As a potent modulator of the host immune response …

Schistosomiasis is a devastating parasitic disease. The mainstay of schistosomiasis control
is by praziquantel treatment. The study aimed to determine benefits of annual chemotherapy …

Background Mass drug administration (MDA) of praziquantel has been the intervention of
choice against schistosomiasis but with limited success in interrupting the transmission. The …

Despite mass drug administration programmes with praziquantel, the prevalence of
schistosomiasis remains high. A vaccine is urgently needed to control transmission of this …

Schistosomiasis control programs are designed to reduce morbidity by providing mass drug
administration (MDA) of praziquantel to at-risk populations. We compared morbidity markers …

Background Schistosomiasis is a disease of major public health importance in sub-Saharan
Africa. Immunoregulation begins early in schistosome infection and is characterized by …

Control of schistosomiasis depends on a single drug, praziquantel, with variable cure rates,
high reinfection rates, and risk of drug resistance. A vaccine could transform schistosomiasis …